OKYO Pharma Limited (OKYO) Wednesday announced promising categorical data from the Phase 2 study of its OK-101 ophthalmic solution in patients with dry eye disease.
Results from the Phase 2 study were analyzed by categorical evaluation of the data set and responder-rate analyses.
The analyses showed that 34.2 percent of patients treated with OK-101 showed both a reduction in conjunctival sum staining and in the pain symptom compared with 20.3 percent on placebo. Similarly, the number of patients with reduction in conjunctival sum staining and burning/stinging symptoms were also higher at 32.9 percent in the OK-101-treated group compared to the 20.3 percent placebo-treated group.
"These analyses have identified conjunctival staining and ocular pain as the highest potential "sign" and "symptom" co-primary endpoints to be explored in the next DED trial of OK-101," OKYO Pharma said in a release.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.